Skip to main content
. 2017 Mar 7;12(3):e0173345. doi: 10.1371/journal.pone.0173345

Fig 1. The prevalence and spectrum of SMAD4 mutations in the MD Anderson study patients and TCGA data.

Fig 1

(A) The prevalence and spectrum of SMAD4 mutations in the study patients who underwent full-length sequencing (n = 49). (B) The prevalence and spectrum of SMAD4 mutations in TCGA data (n = 220 patients).